Monitoring patients to improve physical health and treatment outcome

European Neuropsychopharmacology

Volumn 18, Issue SUPPL. 3, 2008, Pages

  Llorca, Pierre Michel ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Antipsychotic agents; Quality of life; Schizophrenia; Treatment outcome

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; BLOOD EXAMINATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; DOCTOR PATIENT RELATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECG ABNORMALITY; FOLLOW UP; HEALTH PROMOTION; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MENTAL HEALTH; METABOLIC DISORDER; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TORSADE DES POINTES; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

GUIDELINES AS TOPIC; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; METABOLIC DISEASES; MONITORING, PHYSIOLOGIC; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 50049102682     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.04.004     Document Type: Article

References (54)

1. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 62 suppl 7 (2001) 22-31
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 (2004) 596-601
3. Appleby L., Shaw J., Amos T., and McDonnell R. Safer services. National confidential inquiry into suicide and homicide by people with mental illness. © Crown Copyright. Produced by the Department of Health (1999)
4. Baker A., Ricjmond R., Haile M., Lewin T.J., Carr V.J., Taylor R.L., Jansons S., and Wilhelm K. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am. J. Psychiatry 163 (2006) 1934-1942
5. Baumgartner A., Pietzcker A., and Gaebel W. The hypothalamic-pituitary-thyroid axis in patients with schizophrenia. Schizophr. Res. 44 (2000) 233-243
6. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry 171 (1997) 502-508
7. Brown S., Birtwistle J., Roe L., and Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 29 (1999) 697-701
8. Brown S., Inskip H., and Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry 177 (2000) 212-217
9. Carney C.P., Jones L., and Woolson R.F. Medical comorbidity in women and men with schizophrenia: a population-based controlled study. J. Gen. Intern. Med. 21 (2006) 1133-1137
10. Citrome L., and Yeomans D. Do guidelines for severe mental illness promote physical health and well-being?. J. Psychopharmacol. 19 suppl (2005) 102-109
11. Connolly M., and Kelly C. Lifestyle and physical health in schizophrenia. Adv. Psychiatr. Treat. 11 (2005) 125-132
12. de Leon J., Dadvand M., Canuso C., White A.O., Stanilla J.K., and Simpson G.M. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am. J. Psychiatry 152 (1995) 454-455
13. DeLisi L.E., Boccio A.M., Riordan H., Hoff A.L., Dorfman A., McClelland J., Kushner M., Van Eyl O., and Oden N. Familial thyroid disease and delayed language development in first admission patients with schizophrenia. Psychiatry Res. 38 (1991) 39-50
14. Dinan T.G. Schizophrenia and diabetes 2003: an expert consensus meeting. Introduction. Br. J. Psychiatry 184 suppl 47 (2004) s53-s54
15. Dixon L., Postrado L., Delahanty J., Fischer P.J., and Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J. Nerv. Ment. Dis. 187 (1999) 496-502
16. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., and Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 26 (2000) 903-912
17. FDA Psychopharmacological Drugs Advisory Committee July 19, 2000. Available: www.fda.gov/ohrms/dockets/ac/00/slides/3619s1.htm.
18. Glassman A.H. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J. Clin. Psychiatry 66 suppl 6 (2005) 5-10
19. C interval, torsade de pointes, and sudden death. Am. J. Psychiatry 158 (2001) 1774-1782
20. Goldman L.S. Medical illness in patients with schizophrenia. J. Clin. Psychiatry 60 suppl 21 (1999) 10-15
21. Gründer G., Wetzel H., Schlösser R., Anghelescu I., Hillert A., Lange K., Hiemke C., and Benkert O. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol. Psychiatry 45 (1999) 89-97
22. C, in the absence and presence of metabolic inhibition. J. Clin. Psychopharmacol. 24 (2004) 62-69
23. Hughes J.R., Hatsukami D.K., Mitchell J.E., and Dahlgren L.A. Prevalence of smoking among psychiatric outpatients. Am. J. Psychiatry 143 (1986) 993-997
24. Jeste D.V., Gladsjo J.A., Lindamer L.A., and Lacro J.P. Medical comorbidity in schizophrenia. Schizophr. Bull. 22 (1996) 413-430
25. Joukamaa M., Heliövaara M., Knekt P., Aromaa A., Raitasalo R., and Lehtinen V. Mental disorders and cause-specific mortality. Br. J. Psychiatry 179 (2001) 498-502
26. Kelly C., and McCreadie R. Cigarette smoking and schizophrenia. Adv. Psychiatr. Treat. 6 (2000) 327-331
27. Kelly D.L., and Conley R.R. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, fluphenazine. J. Clin. Psychiatry 66 (2005) 80-84
28. Lasser K., Boyd J.W., Woolhandler S., Himmelstein D.U., McCormick D., and Bor D.H. Smoking and mental illness. A population-based prevalence study. JAMA 284 (2000) 2606-2610
29. Lehman A.F., Lieberman J.A., Dixon L.B., McGlasham T.H., Miller A.L., Perkins D.O., Kreyenbuhl J., American Psychiatric Association, and Steering Committee on Practice Guidelines. Practice Guideline for the Treatment of Patients with Schizophrenia. second edition. Am. J. Psychiatry vol. 161 (2004) 1-56 (2 suppl)
30. Marder S.R., Essock S.M., Millar A.L., Buchanan R.W., Davis J.M., Kane J.M., Lieberman J., and Schooler N.R. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr. Bull. 28 (2002) 5-16
31. Marder S.R., Essock S.M., Millar A.L., Buchanan R.W., Casey D.E., Davis J.M., Kane J.M., Lieberman J.A., Schooler N.R., Covell N., Stroup S., Weissman E.M., Wirshing D.A., Hall C.S., Pogach L., Pi-Sunyer X., Bigger J.T., Friedman A., Kleinberg D., Yevich S.J., Davis B., and Shon S. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry 161 (2004) 1334-1349
32. McCreadie R., Macdonald E., Blacklock C., Tilak-Singh D., Wiles D., Halliday J., and Paterson J. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ 317 (1998) 784-785
33. McCreadie R., and on behalf of the Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia. Br. J. Psychiatry 183 (2003) 534-539
34. McCreadie R.G., Stevens H., Henderson J., Hall D., McCaul R., Filik R., Young G., Sutch G., Kanagaratnam G., Perrington S., McKendrick J., Stephenson D., and Burns T. The dental health of people with schizophrenia. Acta. Psychiatr. Scand. 110 (2004) 306-310
35. McIntyre R.S., McCann S.M., and Kennedy S.H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can. J. Psychiatry 46 (2001) 273-281
36. Menezes P.R., Johnson S., Thornicroft G., Marshall J., Prosser D., Bebbington P., and Kuipers E. Drug and alcohol problems among individuals in severe mental illness in south London. Br. J. Psychiatry 168 (1996) 612-619
37. Meyer J.M. Effects of atypical antipsychotics on weight and serum lipid levels. J. Clin. Psychiatry 62 suppl 27 (2001) 27-34
38. Mukherjee S., Decina P., Bocola V., Saraceni F., and Scapicchio P.L. Diabetes mellitus in schizophrenic patients. Compr. Psychiatry 37 (1996) 68-73
39. National Institute for Clinical Excellence (Nice). Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline 1, London (2002)
40. National Institute for Clinical Excellence (Nice). Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology appraisal no. 43, London (2002)
41. Olfson M., Uttaro T., Carson W.H., and Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. J. Clin. Psychiatry 66 (2005) 331-338
42. Othman S.S., Abdul Kadir K., Hassan J., Hong G.K., Singh B.B., and Raman N. High prevalence of thyroid function test abnormalities in chronic schizophrenia. Aust. N. Z. J. Psychiatry 28 (1994) 620-624
43. Petersen L., Nordentoft M., Jeppesen P., Øhlenschlæger J., Thorup A., Østergaard Christensen T., Krarup G., Dahlstrøm J., Haastrup B., and Jørgensen P. Improving 1-year outcome in first-episode psychosis. OPUS trial. Br. J. Psychiatry 187 suppl 48 (2005) s98-s103
44. Phelan M., Stradins L., and Morrison S. Editorial. Physical health of people with severe mental illness. BMJ 322 (2001) 443-444
45. Rao M.L., Strebel B., Halaris A., Gross G., Bräunig P., Huber G., and Marler M. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia. Psychiatry Res. 57 (1995) 21-39
46. Ryan M.C.M., Collins P., and Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug naive patients with schizophrenia. Am. J. Psychiatry 160 (2003) 284-289
47. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., Jatlow P.I., Wexler B.E., and George T.P. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia. Involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatry 62 (2005) 649-659
48. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159 (2002) 561-566
49. Tang W.K., Sun F.C., Ungvari G.S., and O'Donnell D. Oral health of psychiatric in-patients in Hong Kong. Int. J. Soc. Psychiatry 50 (2004) 186-191
50. Taylor D., Paton C., and Kerwin R. The Maudsley 2005-2006 Prescribing Guidelines. 8th Edn. (2005), Taylor & Francis, London
51. TNS Healthcare. Omnibus survey conducted amongst 209 UK general practitioners. Published in: Running on empty: Building momentum to improve well-being in severe mental illness (2005)
52. Volavka J., Czobor P., Cooper T.B., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., and Lieberman J.A. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychiatry 65 (2004) 57-61
53. Weiden P.J., Mackell J.A., and McDonnell D.D. Obesity as a risk factor for antipsychotic non-compliance. Schizophr. Res. 66 (2004) 51-57
54. Wirshing D.A., Pierre J.M., Marder S.R., Saunders C.S., and Wirshing W.C. Sexual side effects of novel antipsychotic medications. Schizophr. Res. 56 (2002) 25-30